719870
Resomer® RG 503 H, Poly(D,L-lactide-co-glycolide)
acid terminated, lactide:glycolide 50:50, Mw 24,000-38,000
Synonym(s):
Poly(D,L-lactide-co-glycolide), PLGA
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Quality Level
form
amorphous
feed ratio
lactide:glycolide 50:50
mol wt
Mw 24,000-38,000
degradation timeframe
<3 months
viscosity
0.32-0.44 dL/g, 0.1 % (w/v) in chloroform(25 °C, Ubbelohde) (size 0c glass capillary viscometer)
transition temp
Tg 44-48 °C
storage temp.
2-8°C
SMILES string
OCC(O)=O.CC(O)C(O)=O
InChI key
XBBVURRQGJPTHH-UHFFFAOYSA-N
Application
Controlled release
Features and Benefits
Controlled release of bioactive agents, sutures and bioabsorbable implantable devices.
Physical form
Biocompatible, biodegradable polymer.
Legal Information
Product of Evonik
RESOMER is a registered trademark of Evonik Rohm GmbH
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Kaamini M Dhanabalan et al.
Biomaterials science, 8(15), 4308-4321 (2020-07-01)
Osteoarthritis (OA) is a joint disease characterized by progressive damage of articular cartilage and the adjoining subchondral bone. Chondrocytes, the primary cells of the cartilage, have limited regenerative capacity and when they undergo stress due to trauma or with aging
Maria Kirzhner et al.
Ophthalmology, 120(6), 1300-1304 (2013-02-13)
To compare wrapped and polymer-coated hydroxyapatite implants in children undergoing primary enucleation with no adjuvant therapies. Retrospective, interventional cohort study. All children undergoing primary enucleation without adjuvant therapies between 1999 and 2009 at a tertiary pediatric cancer hospital. Review and
Teresa Musumeci et al.
International journal of pharmaceutics, 440(2), 135-140 (2012-10-20)
Melatonin, a neurohormone secreted by the pineal gland, is able to modulate intraocular pressure (IOP). The aim of this study was to generate nanoparticle (NPs) sustained release formulations that allow to extend the pre-corneal residence time of melatonin, thus prolonging